Infliximab Limits Injury in Myocardial Infarction.
Christopher LiviaSara S InglisRuben Crespo-DiazSkylar RizzoRyan MahlbergMonique S BagwellMatthew HillestadSatsuki YamadaDhivya Vadhana Meenakshi SiddharthanRaman Deep SinghXing LiD Kent ArrellPaul StalboergerTyra WittAbdallah El SabbaghMunveer RihalCharanjit S RihalAndre TerzicJozef BartunekAtta BehfarPublished in: Journal of the American Heart Association (2024)
Profiling of coronary thrombus aspirates in patients with ST-segment-elevation MI revealed highest association for tumor necrosis factor-α in injury risk. Infliximab-mediated immune modulation offers an actionable pathway to alter MI-induced inflammatory response, preserving contractility and limiting adverse structural remodeling.
Keyphrases
- inflammatory response
- single cell
- ulcerative colitis
- coronary artery
- heart failure
- coronary artery disease
- high glucose
- rheumatoid arthritis
- diabetic rats
- left ventricular
- lipopolysaccharide induced
- toll like receptor
- lps induced
- drug induced
- endothelial cells
- oxidative stress
- atrial fibrillation
- stress induced
- patients with inflammatory bowel disease